Clinic Roundup

• Axelar AB, of Stockholm, Sweden, a Karolinksa Development AB portfolio firm, said an investigator-sponsored Phase I/II study started in the U.S. to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor.